Valuation: Medivir AB

Market Cap 995M 98.99M 87.92M 82.22M 74.93M 141M 9.53B 143M 385M 4.85B 372M 364M 15.59B P/E 2026 *
-12.3x
P/E 2027 * -7.47x
Enterprise Value 777M 77.3M 68.65M 64.2M 58.51M 110M 7.44B 112M 301M 3.79B 290M 284M 12.17B EV / Sales 2026 *
181x
EV / Sales 2027 * 3.96x
Free-Float
63.94%
Yield 2026 *
-
Yield 2027 * -
1 day+6.40%
1 week+4.69%
Current month+3.66%
1 month-12.29%
3 months-4.07%
6 months-27.59%
Current year+315.16%
1 week 1.57
Extreme 1.57
1.78
1 month 1.57
Extreme 1.57
1.98
Current year 0.39
Extreme 0.392
2.88
1 year 0.34
Extreme 0.34
2.88
3 years 0.34
Extreme 0.34
8.25
5 years 0.34
Extreme 0.34
11.84
10 years 0.34
Extreme 0.34
102
Manager TitleAgeSince
Chief Executive Officer 55 24/01/2022
Director of Finance/CFO - 23/03/2026
Chief Tech/Sci/R&D Officer 60 20/02/2023
Director TitleAgeSince
Chairman 76 05/05/2021
Director/Board Member 70 03/05/2018
Director/Board Member 47 05/05/2021
Date Insider Type Main position Quantity % Market Cap. Importance
7/27/26 A
Hallberg Management AB
BuyCompany 6,097,560 0.9868%
6/18/26 A Buy

Chief Financial Officer

18,000 0.0033%
12/5/25 A Buy 90,000 0.0802%
Change 5-day change 1-year change 3-year change Capi.($)
+6.40%+4.69%+17.27%-75.66% 98.99M
+4.16%+3.04%+49.37%+94.17% 74.41B
-2.76%-3.10%+22.46%+75.37% 59.26B
+1.00%-0.67%+4.24%+34.46% 47.14B
-0.40%-4.11%+26.87%+33.72% 42.91B
+0.00%+1.00%+353.00%+691.06% 44.13B
-1.67%-1.71%+2.76%+98.70% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-0.15%-8.00%-29.05%+327.30% 23.71B
Average +0.76%-0.89%+48.66%+135.31% 39.25B
Weighted average by Cap. +0.37%-0.32%+57.42%+150.47%

Financials

2026 *2027 *
Net sales 4.3M 428K 380K 355K 324K 610K 41.2M 618K 1.66M 20.98M 1.61M 1.57M 67.4M 221M 21.97M 19.51M 18.25M 16.63M 31.31M 2.12B 31.74M 85.45M 1.08B 82.48M 80.69M 3.46B
Net income -69.1M -6.88M -6.11M -5.71M -5.21M -9.8M -662M -9.93M -26.75M -337M -25.82M -25.26M -1.08B 92.8M 9.23M 8.2M 7.67M 6.99M 13.16M 889M 13.34M 35.92M 453M 34.67M 33.92M 1.45B
Net Debt -218M -21.69M -19.27M -18.02M -16.42M -30.92M -2.09B -31.34M -84.39M -1.06B -81.45M -79.69M -3.42B -121M -12.04M -10.7M -10M -9.11M -17.16M -1.16B -17.4M -46.84M -590M -45.21M -44.23M -1.9B
Logo Medivir AB
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Employees
6
Date Price Change Volume
02/10/26 SEK 1.698 +6.52% 2,467,581
01/10/26 SEK 1.594 -2.69% 1,319,500
30/09/26 SEK 1.638 -0.36% 1,088,957
29/09/26 SEK 1.644 -1.56% 670,073
28/09/26 SEK 1.670 +2.96% 642,109
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.594SEK
Average target price
5.212SEK
Spread / Average Target
+227.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MVIR B Stock